Incorrect,In Cohort B, two out of three evaluable patients achieved complete responses, with one patient showing a response duration of over 120 days and another exceeding 90 days. These results are encouraging, particularly as the trial incorporates a low dose of interleukin 2 to enhance the durability of the CAR T-cell therapy. All four patients in this cohort, including one still awaiting a 28-day scan, remain on trial.
The overall safety profile of the treatment has been acceptable (look for the news on this "acceptable" term), and the trial will continue to enroll more patients. The positive findings will contribute to a potential Phase 2/3 FDA registration trial
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.3¢ |
Change
0.002(18.2%) |
Mkt cap ! $97.07M | |||
| Open | High | Low | Value | Volume |
| 1.2¢ | 1.4¢ | 1.1¢ | $625.7K | 50.56M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 20 | 5795292 | 1.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.3¢ | 3258567 | 9 |
View Market Depth
| Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
| IMU (ASX) Chart |